TNFα Monoclonal Antibody for Acute Spinal Cord Injury
Status:
Not yet recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of subcutaneous
injection of TNFα monoclonal antibody cells for the treatment of traumatic acute spinal cord
injury. Spinal cord injury can be divided into three phases, which are acute (within 2
weeks), sub-acute (2 weeks to 6 months), and chronic (over 6 months). The pathological
process of spinal cord injury include primary injury (initial traumatic insult) and a
progressive secondary injury cascade characterized by ischemia, proapoptotic signaling,
peripheral inflammatory cell infiltration and the release of proinflammatory cytokines.
Secondary injury plays a key role in the loss of spinal cord function after trauma. So early
treatment to prevent the secondary injury is the key to improve prognosis. TNFα monoclonal
antibody is a TNF-α inhibitor that could control inflammatory response, and now widely used
in the treatment of Ankylosing spondylitis, Rheumatoid arthritis and other autoimmune
diseases. In this study, the investigators will treat patients with acute spinal cord injury
with TNFα monoclonal antibody and compare with the control group.